Home
>
US Stocks
>
Evelo Biosciences Inc

Evelo Biosciences Inc (EVLO)

$0.1514

+0.02

(+17.27%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on Evelo Biosciences Inc

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 129.7%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 119.7%

Performance

  • $0.14
    $0.15
    $0.15
    downward going graph

    9.0%

    Downside

    Day's Volatility :10.49%

    Upside

    1.64%

    downward going graph
  • $0.02
    $3.29
    $0.15
    downward going graph

    83.8%

    Downside

    52 Weeks Volatility :99.26%

    Upside

    95.44%

    downward going graph

Returns

PeriodEvelo Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-75.88%
0.3%
-6.7%
6 Months
-92.85%
-8.3%
-6.2%
1 Year
-92.88%
-4.8%
-6.3%
3 Years
-96.56%
23.8%
26.9%

Highlights

Market Capitalization
17.0M
Book Value
- $0.04
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.12
Wall Street Target Price
1.4
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-89.02%
Return On Equity TTM
-6232.76%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-106.4M
Diluted Eps TTM
-1.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.69
EPS Estimate Next Year
-0.72
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Hold
    10%Buy
    50%Hold
    40%Sell
Based on 10 Wall street analysts offering stock ratings for Evelo Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
9
Hold
5
5
3
Sell
4
4
00

Analyst Forecast

What analysts predicted

Upside of 824.7%

Current $0.15
Target $1.40

Technicals Summary

Sell

Neutral

Buy

Evelo Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Evelo Biosciences Inc
Evelo Biosciences Inc
32.42%
-92.85%
-92.88%
-96.56%
-99.05%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.19%
-3.62%
8.99%
20.86%
140.79%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
23.08%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
14.6%
112.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Evelo Biosciences Inc
Evelo Biosciences Inc
NA
NA
NA
-0.69
-62.33
-0.89
0.0
-0.04
Moderna, Inc.
Moderna, Inc.
11.28
11.28
0.0
-1.96
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.02
20.02
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.02
27.02
0.41
14.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Evelo Biosciences Inc
Evelo Biosciences Inc
Hold
$14.5M
-99.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.2B
578.71%
11.28
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.79%
20.02
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.7B
112.57%
27.02
35.4%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    45.46%

  • FMR Inc

    14.81%

  • State Treasurer State Of Michigan

    3.67%

  • Credit Suisse First Boston (CSFB)

    3.32%

  • Vanguard Group Inc

    2.86%

  • Harbourvest Partners, LLC

    2.76%

Corporate Announcements

  • Evelo Biosciences Inc Earnings

    Evelo Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Organization
Evelo Biosciences Inc
Employees
66
CEO
Dr. Balkrishan Gill Ph.D.
Industry
Health Technology

Discover More

FAQs